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Mitral regurgitation is observed in about 2/3 of patients with aortic
stenosis. Following conventional aortic valve replacement improve-
ment of MR has been observed in about 50% of cases [1]. The impact of
Transcatheter aortic valve implantation (TAVI) on MR is controversial.
Two recent publications have reported improvement in MR grades
following transcatheter aortic valve replacement with the Edwards-
SAPIEN valve system [2,3]. These ﬁndings were not replicated with the
CoreValve system [4]. The time course of improvement in MR grades
with the Edwards-SAPIEN valve has however not been described on an
individual patient basis and the potential mechanisms of the beneﬁt
are unclear.
In the present study the potential beneﬁt of TAVIwith the Edwards-
SAPIEN valve on mitral regurgitation and insights on the mechanisms
was studied by means of serial transthoracic echocardiography.
From September 2008 to September 2009, 22 consecutive patients
with severe aortic stenosis, underwent TAVI with the Edwards-SAPIEN
valve in our institution. All candidates were contraindicated for con-
ventional surgery or considered a high surgical risk with an operative
mortality risk of N20% as assessed by at least 2 cardiovascular surgeons
and 2 cardiologists. The procedures were performed as previously
described [2].
Transthoracic echocardiography was performed pretreatment,
post-treatment, and postdischarge, using a Philips 5500 (Philips,
The Netherlands). MR was graded in 5 groups as none (=0), trivial
(=1), mild (=2), moderate (=3), or severe (=4) [5]. A valvular
insufﬁciency ≥2 was considered signiﬁcant. MR was deﬁned as
organic in the presence of calciﬁcations or myxomatous degenera-
tion of the mitral annulus and/or leaﬂets and functional in case of LV
dysfunction and absence of morphological abnormalities of the
mitral apparatus [4].
For comparison between categorical variables a chi square test was
used. A one-way ANOVA test was used for comparison between con-
tinuous variables. A one-way repeated measures Friedman test with
post-hoc analysis was used to evaluate changes over time. A P-value of
b0.05 was considered statistically signiﬁcant.
The baseline clinical and echo characteristics of the study
population are presented in Table 1. Patients who underwent a TA-
AVI rather than a TF-AVI procedure were more likely to have history of
CAD (p=0.02). The procedure was successful in 21/22 patients (95%).
The patient with an unsuccessful valve implant underwent emergent
conventional surgery and died in-hospital at day 11. Another patient
died in hospital at day 3 from right ventricular failure secondary to an
inferior MI. Within the ﬁrst 30 days, 2 additional patients died, one
from pulmonary infection in the TA-AVI group and one from sudden
death in the TF-AVI group. No stroke was observed. Eighteen patients
were available for echocardiography after discharge.
The echocardiography ﬁndings of the 18 patients with an echo-
cardiography at 1 month are summarized in Table 1. At baseline a
signiﬁcantMRwas observed in 16/22 patients (73%, Table 1). It wasmild,
moderateor severe respectively in8patients (36%), 7patients (32%) and1
patient (4%). It was organic in 6 patients (27%) and functional in 10
patients (46%). The LVend-diastolic diameterwas larger inpatientswith a
signiﬁcant MR compared to those without (48.1±4.4 mm vs 39.8±
1.7 mm; p=0.001). The degree of MR before and after Edwards-SAPIEN
valve implantation in the 18 patients with echocardiography follow-up is
shown in Table 1 and in Fig. 1A. An improvement in MR grades was
observed in these patients (p=0.02, Fig. 1A). This beneﬁt was secondary
to a reduction in MR grades in 6 of the 12 patients (50%) with an MR at
baseline without worsening in the 6 other patients with MR. No
occurrence of MR was observed in the 6 patients without MR at baseline
(Fig.1B). A trend for a greater improvement inMR gradewas observed in
patients with functional MR (n=7,— 1.00±1.0) compared to thosewith
an organic MR (n=5, — 0.29±0.24; p=0.10). Similarly a greater
reduction in LV end-diastolic diameter was associated to a greater
improvement in MR as illustrated by the higher reduction in LV end-
diastolic diameter in the 6 patients with a reduction in MR compared to
the 6without reduction ofMR (2.2±1.1 mmvs0.3±0.9 mm;p=0.009).
The present study is the ﬁrst to demonstrate that the previously
reported beneﬁt in MR grades after implantation of the Edwards
prosthesis [2,3] is secondary to a reduction in MR grades in 50% of
patients with MR at baseline without deleterious effects in the other
50% or in those without MR. Those later results are in contrast with
those recently reported with the CoreValve system [4].
Two recent publications have reported improvement in MR grades
following transcatheter aortic valve replacement with the Edwards-
SAPIEN valve system [2,3]. However in these 2 studies the improvement
was not investigated on an individual patient basis and the mechanism
(s) of the beneﬁt was unclear. The present study conﬁrms these
previous observations and demonstrates that the beneﬁt is secondary
to a reduction in MR grades in 50% of patients with MR without
deleterious effects on the other 50% or in those without MR. It further
demonstrates that the beneﬁt can be observed as early as 1 month post
implantation and is associated with favorable LV diameter remodeling
secondary to the disappearance of the aortic stenosis.
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These results need also be interpreted in light of a serial
echocardiography follow-up of 46 patients who underwent implan-
tation of the CoreValve [4]. Although in their series an improvement
in MR grades was observed in 25% of patients, it was counterbalanced
by a worsening of MR in 22%. More importantly a new MR was
observed in 42% of patients. This deleterious effect could be
secondary to the design of the CoreValve in which the average
depth of implantation is about 8 mmbelow the base of the aortic root
[4] and could alter the normal motion of anterior mitral leaﬂet. The
Edwards-SAPIEN valve, because of its minimal protrusion in
the aortic root [2] would have no or minimal impact on mitral
function thus avoiding to induce orworsenMR. The lack of worsening
of MR or occurrence of newMR in our series supports this hypothesis.
The present ﬁndings provide a potential explanation for the
greater beneﬁt of TAVI with the Edwards-SAPIEN valve in patients
with MR as observed in the PARTNER trial [6]. Finally they provide
additional support to the concept that the differences in design of the
Edwards-SAPIEN valve and the CoreValve system could impact
differently the functionality of the mitral valve. This issue will need
to be tested in a randomized controlled trial.
The authors of this manuscript have certiﬁed that they comply
with the Principles of Ethical Publishing in the International Journal of
Cardiology (Shewan and Coats 2010; 144:1–2).
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Table 1
Patients characteristics at baseline and 1 month follow-up.







Age (year), mean±SD 79±7 78±7 80±8 0.61
Male, n (%) 11 (50) 4 (40) 7 (58) 0.66
BMI, mean±SD 26±5 26±7 26±4 0.85
Hypertension, n (%) 16 (73) 7 (70) 9 (75) 0.80
Atrial ﬁbrillation, n (%) 10 (45) 5 (50) 5 (42) 0.70
Diabetes, n (%) 4 (18) 2 (20) 2 (17) 0.84
Coronary artery disease, n (%) 13 (59) 3 (30) 10 (83) 0.02
Prior myocardial infarction, n (%) 7 (32) 2 (20) 5 (42) 0.38
Percutaneous coronary intervention, n (%) 9 (41) 2 (20) 7 (58) 0.06
Coronary artery bypass, n (%) 6 (27) 2 (20) 4 (33) 0.64
Cerebrovascular events, n (%) 7 (32) 3 (30) 4 (33) 0.87
Peripheral vascular disease, n (%) 2 (9) 0 (0) 2 (17) 0.48
Renal disease, n(%) 5 (23) 2 (20) 3 (25) 0.78
COPD, n (%) 6 (27) 3 (30) 3 (25) 0.79
Logistic Euroscore, mean±SD 21.3±14.1 18.1±15.5 24.1±12.8 0.33
LVEF b35%, n (%) 5 (23) 2 (20) 3 (25) 0.78
LV End-diastolic diameter (mm) 45.7±5.3 45.3±6.1 46.2±4.8 0.71
Aortic valve area (cm2), mean±SD 0.73±0.19 0.73±0.17 0.73±0.21 0.96
Signiﬁcant MR, n (%) 16 (73) 6 (60) 10 (83) 0.34
Type of MR
Organic, n (%) 6 (27) 2 (20) 4 (33) 0.78
Functional, n (%) 10 (46) 4 (40) 6 (50)
Echocardiography ﬁndings during follow-up (N=18) Pre-treatment Post-treatment Post-discharge P*
LV EF b35%, n (%) 3 (23) 2 (15) 3 (17) 0.57
Transfemoral 1 (11) 1 (11) 1 (11)
Transapical 2 (22) 1 (11) 2 (25)
LV end-diastolic diameter (mm)
Transfemoral 45.0±6.3 44.7±5.5 44.3±4.9 0.03
Transapical 46.4±5.5 45.8±5.6 45.1±5.7
Mean Aortic gradient (mmHg) 42±17 9±4 8±3 0.0001
Transfemoral 41±17 12±4 9±3
Transapical 44±18 7±2 7±2
Mitral regurgitation grade (0–4) 2.06±0.94 1.51±1.09 1.41±0.92§ 0.02
Transfemoral 1.89±0.93 1.59±0.93 1.23±0.71
Transapical 2.22±0.97 1.43±1.22 1.59±1.05
All parameters are mean±SD, otherwise stated. P* for reﬂects the difference between the 3 time points by 1-way repeated measures Friedman test. § Pb0.05 compared to “Pre-
treatment” by posthoc analysis of the Friedman test.
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6 patients without significant MR 6 unchanged: no MR
6 patients with mild MR
1 patient with severe MR
5 patients with moderate MR
1 improved: moderate MR
- 4 unchanged: mild MR
- 2 improved: no MR
- 1 unchanged: moderate MR
- 3 improved: mild MR





Fig. 1. A: Changes in mitral regurgitation in the 18 patients with echocardiography follow-up (p=0.02 by 1-way repeated measures Friedman test). B: Individual changes in mitral
regurgitation from pre-treatment to post discharge.
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